Investment Q&A

Q: How much cash does Gud have compared to its market cap and do they have any growing cash generating product. Thinking of selling position and splitting the proceeds with zynex and viemed.

Q: Like many long suffering investors, I am really getting fed up with this stock. I watched a recent interview on BNN with Jonathan Goodman and was not impressed. He had an opportunity to justify why GUD was a public company and completely failed to do so. His message seemed to be if you are not investing for your grandchildren's financial future you might as well forget this stock. I think GUD should at least initiate an initial and rising dividend policy since it has failed to invest much of the large pool of cash being reserved for acquisitions. What do you think of these odds. Thanks.

Q: Could you explain the differences between these two ETFs, if you can call CGOC an ETF. Specifically as to what they invest in, are they actively managed, and their level of risk compared to each other? Your preference of the two, for someone who has a high risk tolerance, who wishes to have some exposure to the industry?

Q: Hi,

Can I get your opinion on SBIO? It's been treating me pretty well.

Thanks

Q: With the stock up 45% in the last year, would you still consider Merck a buy for a long term hold?

Q: I am tired of waiting for GUD to do something. I have 50,000 shares; what would you suggest in trying to sell these?

Q: Hello,

With the news this morning that Profound Medical's clinical trial proved 96% effective for the prostate cancer patients involved in the study, do you see this as a buy? Or is it still considerably risky, given that FDA approval could take some time or be denied?

Thank you.

Brad

Q: What would you recommend if Mr Goodman steps down? Hold? Sell?
Thank you for your service

Q: I would like your opinion on the company. They seem to have a a fair bit of cash and no debt and would like your opinion if this might be a "speculative" stock to invest in.

Q: please comment on today's quarterly report. thanks

Q: Prometic is refilling an amendment to the BLA for plasminogen in H2 2019. If approved this orphan drug with fast track designation comes with a priority voucher possibly worth 100 million. Lazard has 2 deals to close in H2 as well which depend on approval. That said they need cash badly and announced an eminent debt restructuring. There at 20 cents today. What's your best guess on what happens to the float and share price after this. Do they have to give the company away at these to raise 100 million when possibly 200 million is coming their way this year.

Q: My question is regarding Guardant Health. Would you consider this a good time to buy half a position considering it’s recent massive run up and then sell off? It’s always hard to gauge when to step in after such a drop... but there was finally a good day today there was a ton of volume and the stock was up over 4%. Any reason for the big drop? Was it just because the stock had run up so quickly? I have no issues with risk and have a long time frame. Sector is not a concern either.

Q: What Health Care sector Equites would you recommend, looking for dividend and growth.

Q: hello 5i:
due to the lack of health care companies in Canada, I'm looking to the US. Can you compare the companies above and advise which one you favour?
thanks
Paul L

Q: Hi, What will be the new no. of outstanding shares for Savaria, with 5 mln new shares issued and the insider ownership ( Mr Bouroussa and family, with addition of 71,000 committed from new issue) ? Based on 2019 guidance, and taking into account this dilution, what will be the pay out ratio ? Is this dividend 3.5 cents/month sustainable, in your view ? While no one likes a secondary at $14.15 after an issue at $16.60, a year ago, on a positive note, company could pay down a large portion of $101 mln debt, thus strengthening the balance sheet. Is there a silver lining and stock is worth adding at current level for 3% dividend yield and growth ? Also, is there a lock-in period of 4 months for the new shares from April 22, the expected closing date of secondary? Could it place more pressure on the stock, down the road ? Thank You

Q: What are thoughts on the recent quarter, seems the market is scared of a another disaster restructuring deal that BXE is doing.

Anything positive in the quarter worth hanging on to?
Thanks

Q: Hi team,
PLI took a deep dive today. Any particular reason why? I sold them at a loss a couple of months ago and wondered if it's worth getting back in once they hit bottom. I keep thinking there may be money to be made with this stock. Have they hit a bottom or do you think there is still some downside?
Thanks

Q: I am interested in buying the shares of LJPC, considering its huge drop and the potential of good renounce, would you please share your idea about this?

Q: Do you think the proposed nomination of the new directors gets approved by share holders ?
If so, could the new board replace Mr. Goodman.
Can you elaborate as to what is most likely to happen in the next few months ?
Thanks for your advice.

Q: I would like to know if there is any "hanky panky" going on with
SIS and Dejardins. SIS got upgraded by Dejardins from $16 to $17.50 on an earnings miss which made the stock go up over $15. Now Dejardins are the underwriters
of this deal. Also does this type of "you scratch my back and I'll scratch yours"
happen often in the markets?